CPAP associated with low treatment failure than High-Flow Nasal Cannula in acute bronchitis

LILACS, COCHRANE, MEDLINE, and EMBASE From the beginning through June 2022, clinical trials databases were examined for relevant and gray literature. Randomized clinical trials (RCTs) that included kids under 2 with acute, moderate, or severe bronchiolitis served as the inclusion criterion for the literature. Two reviewers independently choose all of the studies and extract the data.

The key findings of this study were:

106 records were found in the initial searches. 

The meta-analysis only included five randomized controlled trials that satisfied the inclusion requirements. 

In the CPAP group and the HFNC group, the risk of invasive mechanical ventilation was not statistically different (very low quality). 

Compared to the HFNC group, the CPAP group had a considerably lower probability of treatment failure (very low quality).

In conclusion, there was probably no discernible difference in the risk of invasive mechanical breathing between HFNC and CPAP. With the highest risk of mild adverse effects, CPAP lowers the probability of therapeutic failure. To verify these findings, more studies are required.

Reference:

Buendía, J. A., Feliciano-Alfonso, J. E., & Laverde, M. F. (2022). Systematic review and meta-analysis of efficacy and safety of continuous positive airways pressure versus high flow oxygen cannula in acute bronchiolitis. In BMC Pediatrics (Vol. 22, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s12887-022-03754-9